ACO E-bulletin, February 2015. Images not displaying below? Enjoy this online
Ce courriel ne s’affiche pas correctement? Affichez-le dans votre navigateur
logo
Canadian HIV Vaccine Initiative (CHVI)
Research and Development
Alliance Coordinating Office (ACO)

alliance-aco.ca

February 2015

Website

About Partners Contact Français
 


Plotting the Course in Regulatory Capacity and Collaboration

Regulatory Capacity Building Workshop: Vaccine Clinical Trial Review from Ebola to HIV
ACO is pleased to partner with Health Canada, the Public Health Agency of Canada and the Global HIV Vaccine Enterprise, in collaboration with the World Health Organization (WHO) and African regulatory agencies, to host a three-day, invitation-only event entitled “Regulatory Capacity Building Workshop: Vaccine Clinical Trial Review from Ebola to HIV”. The workshop will be held in Kigali, Rwanda from March 18 to 20, 2015. This workshop will bring together regulators and agencies engaged in regulatory capacity building to assist the enhancement of review capacity for HIV clinical trials and other urgent public health challenges in Africa. While the context for the workshop is the upcoming HIV clinical trials, the approach will be to look at strategies recently employed to overcome resource constraints faced by national regulatory authorities (NRAs) through the use of joint review processes with other vaccine trials. To this end, the lessons learned through ongoing Ebola vaccine clinical trial reviews as well as recent joint reviews for vaccines against other pathogens will be explored. Read more.

ACO Annual CHVI R&D Alliance Meeting
The ACO Annual CHVI R&D Alliance Meeting in Toronto will take place on April 30, 2015. The theme of this year’s meeting is HIV Vaccine Networks: Collaborations, Partnerships and Outcomes across Sectors and Borders. Included in the mix of speakers are Silvija Staprans of the Bill & Melinda Gates Foundation, Amapola Manrique from the Global HIV Vaccine Enterprise, and Galit Alter from Harvard University. Mark Gurwith of PaxVax Inc. and Mario Filion of Alethia Biotherapeutics will also bring their insights to the table. Canadian speakers will discuss national initiatives and activities including the Canadian HIV Vaccine Initiative and the Federal Action Plan on Vaccine Research, Innovation and Development. We hope you can join us at this full-day ancillary event to the CAHR 2015 conference. We require advanced registration due to limited capacity and to plan for lunch. Please register online by April 15, 2015. Email us: aco@icid.com for more information.

 
 
Webinar
 

Upcoming Webinar

Science Communication: From Page to Stage

Date: Wednesday, March 18, 2015
Time: 1:00 - 2:45 PM EDT (12:00-1:45 PM CDT, 11:00 AM - 12:45 PM MDT and 10:00 - 11:45 AM PDT)
Presenter: Dr. Jennifer Gardy, Senior Scientist, BC Centre for Disease Control; Assistant Professor, School of Population and Public Health, UBC; Associate Member, Microbiology, UBC

→ READ MORE

News
 

News and Features

HIV R4P 2014 Video Feature

Dr. Ken Rosenthal

As part of the recap on HIV Research for Prevention (HIV R4P) Conference in Cape Town, South Africa we are profiling some Canadian researchers and their poster presentations. This month we feature Dr. Ken Rosenthal of McMaster University, principal investigator of a large-team grant funded through the CHVI.

→ WATCH THE VIDEO

Timely Topics

In 2012, the Global HIV Vaccine Enterprise launched Timely Topics in HIV Vaccines, a strategy series convening experts as rapidly as possible to analyze, address, and respond to unresolved and emerging priority issues in the field. Through an open call for proposals, the Enterprise is working to identify the most important strategic needs of the field and sponsoring think tanks, meetings, forums and other events to tackle these issues. The following are among the projects that have emerged from Timely Topics:

Pan-African Vaccine Agenda
Advancing the African HIV vaccine development agenda
March 16-17, 2015

Target Product Profile
Identifying purpose, value, and process for developing a TPP
June 2015

Visualizing the Immune Landscape
Analysis of expected immune responses for candidate vaccines
August 2015

Product Development Boot Camp
Training on concepts and tools used by industry
September to October 2015

HIV/AIDS Epi Update – Chapter 8: HIV/AIDS among Aboriginal People in Canada

The Public Health Agency of Canada has just released HIV/AIDS Epi Update – Chapter 8: HIV/AIDS among Aboriginal People in Canada. The publication will be available on the PHAC website in February 2015 (http://www.phac-aspc.gc.ca/aids-sida/publication/epi/2010/index-eng.php)

network
 

Funding Opportunities

Canadian Institutes of Health Research

Operating Grant: Transitional Operating Grant: 2014-2015 Priority Announcements
Application Deadline: March 2, 2015
HIV/AIDS (HOP/HHP/HBF)
LEARN MORE

Catalyst Grant : HIV/AIDS Community-Based Research (2015)
Application Deadline: April 15, 2015
The total amount available for this funding opportunity is $198,000, enough to fund approximately six grants. The maximum amount per grant is $33,000 for up to one year.
LEARN MORE

Knowledge Synthesis Grant: Spring 2015 Competition
Application Deadline: May 15, 2015
LEARN MORE

→ Full list of CIHR opportunities

Michael Smith Foundation for Health Research (MSFHR) Post-Doctoral Fellowships
Letter of intent deadline: March 17, 2015
Full application deadline: April 20, 2015
LEARN MORE

 
microscope
 

New Research

Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

J Clin Invest, 2015 Feb 2. pii: 78280. doi: 10.1172/JCI78280.
[Epub ahead of print]
Quinn KM, Zak DE, Costa A, et al

Recombinant adenoviral vectors (rAds) are lead vaccine candidates for protection against a variety of pathogens, including Ebola, HIV, tuberculosis, and malaria, due to their ability to potently induce T cell immunity in humans. However, the ability to induce protective cellular immunity varies among rAds. Here, researchers assessed the mechanisms that control the potency of CD8 T cell responses in murine models following vaccination with human-, chimpanzee-, and simian-derived rAds encoding SIV-Gag antigen (Ag).

→ READ MORE

 


Annual Update

  Annual Update


Annual Update PDF


You are receiving this email because you registered to receive news updates from the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office
or you are a member of a CHVI-funded
project team.

 

Follow Us:

facebook

Facebook

twitter Twitter
share Share with
colleagues
email us Email us
 
 

Address

ALLIANCE COORDINATING OFFICE
International Centre for Infectious Diseases
515 Portage Avenue
Winnipeg, MB, Canada
R3B 2E9
Tel.: 204 946 0908
Fax: 204 946 0927
email:
aco@icid.com

 
 

About Us

The CHVI Research and Development Alliance Coordinating Office (ACO) was established by the Government of Canada and the Bill & Melinda Gates Foundation in November 2011 at the International Centre for Infectious Diseases (ICID), a
not-for-profit,
non-governmental organization based in Winnipeg.

 

White Paper

whitepapers

The ACO has developed a White Paper to foster effective coordination of key players across the Canadian HIV vaccine research landscape.

Read more

 

Conferences

February 23 to 26, 2015
Conference on Retroviruses and Opportunistic Infections (CROI 2015)
Seattle, United States

March 22 to 27, 2015
Keystone Symposium: HIV Vaccines (X5)
Banff, Canada

April 30 to May 3, 2015
CAHR 2015
Toronto, Canada

May 14 to 16, 2015
CANAC: Canadian Association of Nurses in AIDS Care
Ottawa, Canada

June 9 to 12, 2015
7th SA AIDS Conference
Durban, South Africa

July 19 to 22, 2015
IAS 2015
8th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention

Vancouver, Canada

September 13 to 16, 2015
World STI & HIV 2015 Congress
Brisbane, Australia

See full list of conferences



Production of this newsletter has been made possible through a financial contribution from the Public Health Agency of Canada. The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.

Third-Party E-bulletin Disclaimer
This E-Bulletin contains links to third party websites ("Linked Sites"), which are not under the control of ACO and ACO is not responsible for the contents of any Linked Site, including any link contained in a Linked Site or any changes or updates to a Linked Site. The Linked Sites may not be available in French or English. ACO is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by ACO of the Linked Site or any association with its operators. We do not guarantee the accuracy of any information accessed through or published or provided by the Linked Site. You are responsible for viewing and abiding by the privacy statements and terms of use posted at the Linked Sites. Any specific comments or inquiries regarding the Linked Sites should be directed to the operator of the Linked Site.


Copyright © 2015
Canadian HIV Vaccine Initiative Research and Development Alliance Coordinating Office

Update Subscription Preferences

Privacy Policy

Unsubscribe

Subscribe

Send to a Friend

 
eNewsletter powered by eTouchServices

The ACO E-Bulletin is deployed on behalf of the ACO by eTouchServices.
162-2025 Corydon Ave. Suite 103 Winnipeg, MB R3P 0N5 Canada